Streetbeat News

Stock Prices

NBN

Northeast Bank has announced the purchase of primarily commercial real estate loans totaling $805 million since June 30, 2024. This move indicates a strategic focus on expanding its loan portfolio in the commercial real estate sector.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 12:41 pm

CRH

FMAT

PKB

CRH PLC announced that CEO Albert Manifold will retire at the end of 2024, with CFO Jim Mintern set to succeed him. The company has focused on succession planning, ensuring a smooth transition. CRH shares are down 0.94% premarket. Investors can access CRH through ETFs like Invesco Building & Construction ETF (PKB) and Fidelity MSCI Materials Index ETF (FMAT).

Portfolio Pulse from Lekha Gupta

September 24, 2024 | 12:35 pm

BIDU

BP

FHN

MCK

REGN

Several top Wall Street analysts have downgraded their ratings for major companies, including Baidu, BP, McKesson, Regeneron Pharmaceuticals, and First Horizon Corporation. These downgrades reflect a shift in analyst sentiment and could impact the stock prices of these companies in the short term.

Portfolio Pulse from Avi Kapoor

September 24, 2024 | 12:34 pm

CRMT

America's Car-Mart shares rose following the appointment of Jamie Fischer as the new Chief Operating Officer.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 12:31 pm

SCNX

TRxADE Health, Inc. has rebranded to Scienture Holdings, Inc. and changed its Nasdaq ticker symbol from 'MEDS' to 'SCNX'. The company will continue to operate as a pharmaceutical product company through its subsidiaries.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 12:29 pm

THO

Thor Industries reported a Q4 earnings beat with EPS of $1.68 and sales of $2.534 billion, surpassing expectations. However, the FY25 forecast fell short, with anticipated sales between $9.0 billion and $9.8 billion, below the $10.49 billion estimate. THO shares are trading lower by 2.97% premarket.

Portfolio Pulse from Nabaparna Bhattacharya

September 24, 2024 | 12:19 pm

BIIB

Biogen and UCB's Phase 3 study of dapirolizumab pegol for systemic lupus erythematosus met its primary endpoint, showing improvement over placebo. A second Phase 3 trial is planned for 2024. Biogen's stock rose 1.66% in premarket trading.

Portfolio Pulse from Vandana Singh

September 24, 2024 | 12:19 pm

ICCM

IceCure Medical Ltd. (NASDAQ: ICCM) announced the publication of its ICE3 trial results in the Annals of Surgical Oncology, showing a 96.3% recurrence-free rate for early-stage, low-risk breast cancer treated with ProSense cryoablation. The publication precedes an FDA Advisory Panel Meeting for marketing authorization of ProSense, scheduled for November 7, 2024.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 12:17 pm

LIPO

Lipella Pharmaceuticals provided an update on their Phase 2a trial of LP-310 for treating Oral Lichen Planus. Three participants completed the four-week treatment, which was well tolerated and had no unpleasant taste.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 12:16 pm

DELL

Dell Technologies has rejoined the S&P 500 Index as it marks its 40th anniversary and continues to expand its leadership in AI. Since 2023, Dell has returned $9 billion to shareholders.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 12:15 pm